Matches in SemOpenAlex for { <https://semopenalex.org/work/W2793669309> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W2793669309 endingPage "S114" @default.
- W2793669309 startingPage "S113" @default.
- W2793669309 abstract "To assess the efficacy and safety of selective internal radiation therapy (SIRT) with SIR-Spheres Y-90 resin microspheres in heavily pretreated patients with liver metastases from pancreatic adenocarcinoma. From 2011 through 2017, 35 patients (27 men, 8 women; mean age 62.9 y) with metastatic pancreatic adenocarcinoma were treated with SIR-Spheres microspheres at 3 institutions and monitored with laboratory and imaging studies for 4-12 wk. Before SIRT, 34 patients had ≥1 chemotherapy lines, 11 had external beam radiation therapy, 12 had pancreatic surgery, 14 had pancreatic radiation, and 8 had other liver-directed therapies; 23 patients also had adjuvant chemotherapy. Tumor response was assessed with RECIST 1.1 and adverse events graded with CTCAE v4.0. Kaplan-Meier analyses were used to evaluate survival and combined with log-rank tests to identify predictors of survival. Imaging between 4 and 12 wk in 27 patients showed partial response in 8 (29.6%), stable disease in 10 (37.0%), and progressive disease in 2 (7.4%) (7 not determined). Liver function tests showed a significant reduction of mean serum albumin after SIRT (from 3.7 ± 0.53 g/dL [baseline] to 3.3 ± 0.64 g/dL [week 4, P<.001] and 3.0 ± 0.70 g/dL [week 12, P<.001]), and a significant increase in mean ALP values (from 218.0 ± 174.47 IU/L [baseline] to 244.9 ± 132.49 IU/L [week 8, P = .008] and 313.9 ± 144.73 IU/L [week 12, P = .002]). Mean ALT, AST, and total bilirubin were mostly within normal range during the 12-week follow-up. Most frequent SIRT-related adverse events included fatigue (26 patients), abdominal pain (20), nausea (12), weight loss (11), and abdominal disturbances (9). Most complications were grade 1-2; only 3 patients had grade 3 (abdominal distension and ascites, and abdominal pain and fatigue) or grade 4 (AST and ALT elevation) toxicities. Median survival from diagnosis was 20.8 mo. Age, sex, extrahepatic disease, and ECOG performance status were not significant predictors of survival. Y-90 SIRT meaningfully prolonged survival of heavily pretreated patients with liver metastases from pancreatic adenocarcinoma. Complications and liver toxicity remained acceptable and were rarely severe (grade ≥3)." @default.
- W2793669309 created "2018-03-29" @default.
- W2793669309 creator A5008650864 @default.
- W2793669309 creator A5027265213 @default.
- W2793669309 creator A5038529113 @default.
- W2793669309 creator A5044175052 @default.
- W2793669309 date "2018-04-01" @default.
- W2793669309 modified "2023-10-18" @default.
- W2793669309 title "3:18 PM Abstract No. 263 Multicenter evaluation of yttrium-90 selective internal radiation therapy for the treatment of metastatic pancreatic adenocarcinoma" @default.
- W2793669309 doi "https://doi.org/10.1016/j.jvir.2018.01.294" @default.
- W2793669309 hasPublicationYear "2018" @default.
- W2793669309 type Work @default.
- W2793669309 sameAs 2793669309 @default.
- W2793669309 citedByCount "0" @default.
- W2793669309 crossrefType "journal-article" @default.
- W2793669309 hasAuthorship W2793669309A5008650864 @default.
- W2793669309 hasAuthorship W2793669309A5027265213 @default.
- W2793669309 hasAuthorship W2793669309A5038529113 @default.
- W2793669309 hasAuthorship W2793669309A5044175052 @default.
- W2793669309 hasBestOaLocation W27936693091 @default.
- W2793669309 hasConcept C121608353 @default.
- W2793669309 hasConcept C126322002 @default.
- W2793669309 hasConcept C143998085 @default.
- W2793669309 hasConcept C197934379 @default.
- W2793669309 hasConcept C2776694085 @default.
- W2793669309 hasConcept C2778019345 @default.
- W2793669309 hasConcept C2778822529 @default.
- W2793669309 hasConcept C2779185275 @default.
- W2793669309 hasConcept C2779984678 @default.
- W2793669309 hasConcept C2780210213 @default.
- W2793669309 hasConcept C2781182431 @default.
- W2793669309 hasConcept C2989005 @default.
- W2793669309 hasConcept C509974204 @default.
- W2793669309 hasConcept C71924100 @default.
- W2793669309 hasConcept C90924648 @default.
- W2793669309 hasConceptScore W2793669309C121608353 @default.
- W2793669309 hasConceptScore W2793669309C126322002 @default.
- W2793669309 hasConceptScore W2793669309C143998085 @default.
- W2793669309 hasConceptScore W2793669309C197934379 @default.
- W2793669309 hasConceptScore W2793669309C2776694085 @default.
- W2793669309 hasConceptScore W2793669309C2778019345 @default.
- W2793669309 hasConceptScore W2793669309C2778822529 @default.
- W2793669309 hasConceptScore W2793669309C2779185275 @default.
- W2793669309 hasConceptScore W2793669309C2779984678 @default.
- W2793669309 hasConceptScore W2793669309C2780210213 @default.
- W2793669309 hasConceptScore W2793669309C2781182431 @default.
- W2793669309 hasConceptScore W2793669309C2989005 @default.
- W2793669309 hasConceptScore W2793669309C509974204 @default.
- W2793669309 hasConceptScore W2793669309C71924100 @default.
- W2793669309 hasConceptScore W2793669309C90924648 @default.
- W2793669309 hasIssue "4" @default.
- W2793669309 hasLocation W27936693091 @default.
- W2793669309 hasOpenAccess W2793669309 @default.
- W2793669309 hasPrimaryLocation W27936693091 @default.
- W2793669309 hasRelatedWork W2045677062 @default.
- W2793669309 hasRelatedWork W2166944779 @default.
- W2793669309 hasRelatedWork W2270074371 @default.
- W2793669309 hasRelatedWork W2335858412 @default.
- W2793669309 hasRelatedWork W2443798880 @default.
- W2793669309 hasRelatedWork W2569260518 @default.
- W2793669309 hasRelatedWork W2743577629 @default.
- W2793669309 hasRelatedWork W2917037452 @default.
- W2793669309 hasRelatedWork W4226293197 @default.
- W2793669309 hasRelatedWork W4296330869 @default.
- W2793669309 hasVolume "29" @default.
- W2793669309 isParatext "false" @default.
- W2793669309 isRetracted "false" @default.
- W2793669309 magId "2793669309" @default.
- W2793669309 workType "article" @default.